Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment response

Jamie L. Felton¹,², Kurt J. Griffin³, Richard A. Oram⁴, Cate Speake⁵, S. Alice Long⁶, Suna Onengut-Gumuscu⁷, Stephen S. Rich⁷, Gabriela SF Monaco¹,², Carmella Evans-Molina¹,⁸, Linda A. DiMeglio¹,², Heba M. Ismail¹, Andrea K. Steck⁹, Dana Dabelea⁸, Randi K. Johnson¹¹-¹², Marzhan Urazbayeva¹³, Stephen Gitelman¹⁴, John M. Wentworth¹⁵, Maria J. Redondo¹³* and Emily K. Sims¹-²* on behalf of the ADA/EASD Precision Medicine in Diabetes Initiative Consortium

*Joint senior authors

¹Department of Pediatrics, Center for Diabetes and Metabolic Diseases, ²Herman B Wells Center for Pediatric Research, Indiana University School of Medicine
³Department of Pediatrics, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA and Sanford Research, Sioux Falls, SD, USA
⁴NIHR Exeter Biomedical Research Centre (BRC), University of Exeter, Exeter, UK
⁵Academic Kidney Unit, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK
⁶Centers for Interventional Immunology, and ⁷Translational Immunology, Benaroya Research Institute, Seattle, WA, USA
⁸Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA
⁹Richard L. Roudebush VAMC, Indianapolis, IN, USA
¹⁰Barbara Davis Center for Adiposity and Diabetes (LEAD) Center, and ¹¹Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, CO, USA
¹²Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.
¹³Department of Pediatrics, Baylor College of Medicine
¹⁴Department of Pediatrics, Diabetes Center; University of California at San Francisco, San Francisco, CA USA
¹⁵Royal Melbourne Hospital Department of Diabetes and Endocrinology, Parkville, Vic, Australia; Walter and Eliza Hall Institute, Parkville, Vic, Australia; University of Melbourne Department of Medicine, Parkville, Vic, Australia.

Word count: 4339
Abstract

Background
Type 1 diabetes (T1D) results from immune-mediated destruction of insulin-producing beta cells. Efforts to prevent T1D have focused on modulating immune responses and supporting beta cell health; however, heterogeneity in disease progression and responses to therapies have made these efforts difficult to translate to clinical practice, highlighting the need for precision medicine approaches to T1D prevention.

Methods
To understand the current state of knowledge regarding precision approaches to T1D prevention, we performed a systematic review of randomized-controlled trials from the past 25 years testing disease-modifying therapies in T1D and/or identifying features linked to treatment response, analyzing bias using a Cochrane-risk-of-bias instrument.

Results
We identified 75 manuscripts, 15 describing 11 prevention trials for individuals with increased risk for T1D, and 60 describing treatments aimed at preventing beta cell loss in individuals at disease onset. Seventeen agents tested, mostly immunotherapies, showed benefit compared to placebo (only two prior to T1D onset). Fifty-seven studies employed precision analyses to assess features linked to treatment response. Age, measures of beta cell function and immune phenotypes were most frequently tested. However, analyses were typically not prespecified, with inconsistent methods reporting, and tended to report positive findings.

Conclusions
While the quality of prevention and intervention trials was overall high, low quality of precision analyses made it difficult to draw meaningful conclusions that inform clinical practice. Thus, prespecified precision analyses should be incorporated into the design of future studies and reported in full to facilitate precision medicine approaches to T1D prevention.

Plain Language Summary
Type 1 diabetes (T1D) results from the destruction of insulin-producing cells in the pancreas, necessitating lifelong insulin dependence. T1D prevention remains an elusive goal, largely due to immense variability in disease progression. Agents tested to date in clinical trials work in a subset of individuals, highlighting the need for precision medicine approaches to prevention. We systematically reviewed clinical trials of disease-modifying therapy in T1D. While age, measures of beta cell function, and immune phenotypes were most commonly identified as factors that influenced treatment response, the overall quality of these studies was low. This review reveals an important need to proactively design clinical trials with well-defined analyses to ensure that results can be interpreted and applied to clinical practice.
Introduction

Type 1 diabetes (T1D) results from immune-mediated destruction of pancreatic beta cells\(^1\). Since the discovery of insulin over a century ago, treatment options for persons with type 1 diabetes (T1D) have shown remarkable advancements, including improved insulin formulations, delivery methods, and tools to monitor glycemia \(^2\). Even with these transformative advances, considerable negative impacts remain on health outcomes and quality of life \(^3-5\). Therapies targeting the underlying pathophysiology of T1D could delay, prevent, or reverse the need for insulin replacement. Many therapies have been proposed and tested as potential agents for disease modification with an ultimate goal of T1D prevention. In 2022, the US Food and Drug Administration approved teplizumab, a monoclonal antibody targeting CD3, as the first therapy to delay the onset of clinical T1D in at-risk individuals \(^6\).

Autoimmune beta cell destruction leads to progressive hyperglycemia, abnormal glucose tolerance and eventually clinical T1D diagnosis. This progression is also reflected in C-peptide decline, accelerating in the last preclinical stages before diagnosis and continuing after diagnosis \(^7\). Because T1D is an autoimmune disease, most agents tested as potential disease modifying therapies are immunomodulatory, while others target pathologic contributors such as glucose toxicity and beta cell health and function \(^6\). Many agents that hold promise in T1D prevention are first tested in individuals at the time of T1D diagnosis because of the more favorable risk-benefit ratio coupled with an increased ease of identifying eligible trial participants.
The Precision Medicine in Diabetes Initiative (PMDI) was established in 2018 by the American Diabetes Association (ADA) in partnership with the European Association for the Study of Diabetes (EASD). The ADA/EASD PMDI includes global thought leaders in precision diabetes medicine who are working to address the burgeoning need for better diabetes prevention and care through precision medicine. This Systematic Review is written on behalf of the ADA/EASD PMDI as part of a comprehensive evidence evaluation of precision prevention in T1D in support of the 2nd International Consensus Report on Precision Diabetes Medicine. The first ADA/EASD Precision Medicine in Diabetes Consensus Report defined precision prevention as “using information about a person’s unique biology, environment, and/or context to determine their likely responses to health interventions” and states that “precision prevention should optimize the prescription of health-enhancing interventions” \(^9\). Given that agents targeting these pathways may have potential adverse effects, and initial therapies may affect efficacy and safety of subsequent treatment approaches, precision medicine is uniquely poised to identify which individuals stand to benefit the most from a given intervention, and to optimize potential risk-benefit ratios for treated-persons. Additionally, once further T1D disease-modifying therapies are approved for clinical use, precision medicine will facilitate selection of therapies guided by the individual’s disease, including potential combination regimens of disease-modifying therapies \(^{10,11}\).

Therefore, we sought to understand the current state of knowledge regarding precision approaches to T1D disease modification, either to prevent development of clinical disease or its progression. Specifically, we asked if individual characteristics have been
robustly identified to select persons for therapeutic optimization of T1D disease-modifying therapies before or at the time of diagnosis. We reviewed and summarized existing trials in this area and identified individual characteristics associated with treatment effects.

**Methods**

Data Source: We developed a search strategy using an iterative process that involved Medical Subject Headings (MeSH) and text words. This search was refined based on a sensitivity check for key articles identified by members of the group (Supplemental Figure 1). This strategy was applied to PubMed and EMBASE databases by librarians from Lund University on 2/22/2022.

Study Selection: The Covidence platform was utilized for stages of systematic review. To qualify for review, studies must have tested a disease-modifying treatment in either initially non-diabetic individuals at risk, or individuals with new onset stage 3 type 1 diabetes (within 1 year of diagnosis). Eligible study types included randomized controlled trials (RCTs); systematic reviews or meta-analyses of RCTs, or post-hoc analyses of RCTs. Selected primary trials or longitudinal follow-up papers of primary trials had a total sample size >=50 and were published as a full paper in English in a peer-reviewed journal within 25 years of the search (2/21/1997-2/22/2022). Papers focusing on a precision approach to identify features associated with a treatment response were also included as long as the total sample size was >10. Longitudinal follow-up papers of RCTs were included if they addressed follow-up data on time to
diabetes, C-peptide area under the curve (AUC), or included precision analyses aiming to identify measures or markers of treatment response. Studies were excluded if they included mixed participant populations (i.e. type 1 and type 2 diabetes) or populations with inconsistent definitions across papers (i.e. latent onset diabetes in adults). Several additional key articles identified by the group of experts that also met inclusion criteria but not included in the search results because of search restrictions designed to improve search feasibility were also included in the analysis.

Investigators independently screened and reviewed each potentially relevant article according to preliminary eligibility criteria determined by members of the review team. For Level 1 screening two investigators per article screened each title and abstract. Discordant assessments were discussed and resolved by consensus or arbitration after consultation with a member of the review leadership team (JLF, RO, KJG, MR, or EKS). For Level 2 screening of eligible articles, full texts were retrieved and reviewed by two independent reviewers using the inclusion/exclusion criteria. Discordant assessments were similarly discussed and resolved.

Data Extraction: Two separate investigators per article extracted data from each article meeting inclusion criteria, with consensus determined by a member of the leadership team. Extracted data included participant characteristics, intervention details, outcomes of intervention on time to diabetes or C-peptide, and methods and findings surrounding precision analyses focused on treatment response. Investigators also performed quality assessments using Covidence’s Cochrane Risk of Bias template in tandem for each
eligible study; this included assessments of sequence generation, allocation concealment, masking of participants/personnel, masking of outcome assessment, incomplete outcome data, selective reporting, and any other sources of bias to order to determine overall risk of bias.

Data Analysis and Synthesis: Because of heterogeneity of clinical interventions (e.g., agent tested, study design, analytical methodology, etc.) we were unable to perform a meta-analysis but instead completed summaries of relevant studies. The protocol of this review was registered at Prospero.com before implementation (available at https://www.crd.york.ac.uk/PROSPEROFILES/310063_PROTOCOL_20221110.pdf).

Results

Systematic Review Results

From 1005 studies identified by PubMed and Embase searches, 75 were eligible for extraction (Figure 1). This included original trial papers, trial longitudinal follow-up papers, and papers focused specifically on a precision analysis surrounding treatment response in prevention trials (15 papers from 11 prevention trial cohorts)\(^ {12-26}\) and in individuals with new onset T1D (60 total papers from 45 new onset trial cohorts)\(^ {27-86}\).

The 15 articles on T1D prevention generated from 11 trials are summarized in Table 1. Primary prevention studies in genetically at-risk individuals testing development of islet
autoantibodies or time to T1D comprised 27% (3/11) of trials; 63% (7/11) of trials were secondary prevention studies testing effects of interventions in autoantibody positive individuals on time to T1D; one trial tested both genetically at-risk infants and autoantibody positive siblings. Further inclusion criteria for trials included measures of beta cell function, with studies testing antigen-based therapies utilizing specific autoantibody positivity criteria. The DPT-1 oral and parental insulin studies and TrialNet oral insulin study identified participants based on insulin autoantibody positivity and first phase insulin response on intravenous (IV) glucose tolerance testing. The TrialNet teplizumab prevention study only enrolled individuals with dysglycemia on oral glucose tolerance testing. Finally, a study testing glutamic acid decarboxylase (GAD) antigen therapy was limited to individuals who were GAD autoantibody positive. Most prevention trials (9/11; 81%) were multicenter studies; 9/11 (82%) were also double masked, while 2/11 (18%) had no masking. In addition to these 11 papers, two follow-up papers and two papers focused solely on precision analysis of treatment response were also identified (for a total of 15 papers). Overall, only two prevention studies reported a positive impact on time to islet autoantibody positivity or time to diabetes: the primary prevention study testing whey-based hydrolyzed vs cow’s milk formula and the secondary prevention study testing teplizumab (Fig. 2).

The 60 manuscripts generated from 45 trials in the new-onset T1D population included 42 primary trial papers, 6 trial longitudinal follow-up papers and 12 papers focused solely on precision analyses of treatment response (Fig. 1). Additional characteristics of these 60 papers are summarized in Supplemental Table 1. Here, except for variable
age criteria, inclusion criteria were more homogeneous than in prevention studies, typically including participants with a clinical diagnosis of T1D (usually with islet autoantibody positivity) and C-peptide above a certain cutoff. Of the 43 trials, 30 (70%) included both adults and children, 9 (21%) tested only children, and 4 (9%) were performed solely in adults. Five trials had inclusion criteria that included positivity for a specific islet autoantibody. Trials described were typically multicenter studies (39/43; 91%) and double masked (35/43; 81%). Two studies were single masked, two described only masked outcomes testing, three had no masking, and masking was not described in one study.

A measure of beta cell function was by far the most common primary outcome specified amongst new onset trials (single primary outcome in 33/43 (77%), co-primary outcome in 2/43; 5%), although other studies used HbA1c and/or insulin dose and one study used T1D remission. Primary outcome was not specified in 5 trials. All follow-up studies focused on a measure of beta cell function. Trials reporting a measure of beta cell function as the primary outcome most commonly utilized mean C-peptide AUC from a mixed meal tolerance test; values for these data were available for 32/35 primary trials and 5/6 follow up studies and are summarized in Supplemental Table 2. Of trial manuscripts reporting these data, less than a fourth identified a positive effect of the intervention on mean C-peptide AUC. These included trials testing imatinib mesylate, low dose anti-thymocyte globulin, teplizumab (anti-CD3 antibody), otelixizumab (anti-CD3 antibody), abatacept (CTLA4-Ig), rituximab (anti-CD20 antibody), golimumab (anti-
TNF-alpha), recombinant IFN alpha, and combination of anti-IL-21 antibody with liraglutide.

**Precision analyses focused on features associated with disease-modifying treatment response**

To determine whether there were specific features that impacted response to treatment (genetic, metabolic, immune), we assessed papers that included this type of precision analysis. Two papers from prevention and the 12 papers from new onset studies focused solely on precision analyses of treatment response (ie, no analysis of primary trial or longitudinal follow-up analysis of primary trial). An additional 43 papers also included some aspect of precision analysis (summarized in Supplemental Table 3).

As shown in Fig. 3A, of 57 total papers identified, most (38/57; 67%) were primary trial papers with a section focused on features of treatment response. Just over half of the primary trial follow-up papers (5/8; 63%) included precision analyses of treatment response.

While precision analysis of treatment response was commonly reported, this was rarely pre-specified, occurring in just 16/57 (28%) of papers studied (Fig. 3B). Prespecified precision analyses were more common in primary trial or primary trial follow-up papers.

For primary trials, 34% (13/38) of precision analyses were prespecified, and 10.5% (4/38) had both pre-specified and post-hoc analyses. For follow-up papers 40% (2/5) were pre-specified. In contrast, only 7% (1/14) of papers focused specifically on precision analyses described a prespecified analysis plan. Analyses tended to identify a
positive relationship with treatment effect (Fig. 3C), with 37/57 (67%) studies identifying a significant relationship between a feature and treatment response. This was more prevalent for precision analyses in primary trial follow-up papers (5/5; 100%) and in precision analysis-only papers (13/14; 93%).

Because sample sizes inevitably decrease as groups are subdivided for precision analyses, we next looked at sample sizes for the precision subgroups. Only slightly over half (30/57) of papers reported sample sizes for all subgroups defined by precision features. Within these 30 manuscripts, we observed wide variability in sample sizes of subgroups analyzed. Fig. 3D displays reported values for the smallest subgroup sample size described. Overall median values were 11 (interquartile range of 7-19) participants, and ranged from 2-128 participants.

Fig. 4A displays the number of precision features tested for each paper. For all papers, the median number of features tested was 3 (interquartile range of 1-7). This tended to be higher in papers focused solely on precision analyses (median of 6.5 with several papers testing numerous subgroups as part of sequencing, array, or flow cytometry analysis). Forty-one papers analyzed multiple precision features. Of these applicable analyses, corrections for multiple comparisons were either not mentioned or not performed in 35/41 (85%) of papers, particularly for trials (100% of applicable papers with multiple comparisons not described or not performed) (Figure 4B).
We next examined the types of features tested for relationships with treatment response (Fig. 4C). In trial papers and follow up papers, age was most commonly tested (>3/4 of analyses), followed by a measure of beta cell function (>1/2 of analyses). Only 9/36 (25%) studies testing age identified a significant relationship with treatment response; these were all in the new onset period 27,36,41,43,49,53,56,79,82. Here, younger age groups showed improved treatment responses to teplizumab, ChAglyCD3, and Vitamin E 36,49,53,56,79,82. In contrast older age was linked to a beneficial treatment response vs. placebo with high-dose antithymocyte globulin (ATG) and oral insulin (both studies with negative findings overall) 41,43. One study showed that younger age was linked to a more rapid decline of C-peptide compared to placebo in Bacillus Calmette-Guerin (BCG) vaccine-treated individuals 27. Baseline measures of beta cell function were linked to differences in treatment response in 10/26 (38%) of analyses where this relationship was tested 16,19,35,42,49,55,56,68,83,84. In two papers focused on prevention studies, measures linked to worsened beta cell function were associated with an improved response to treatment (with oral insulin or teplizumab) 16,19. Analyses testing trials in the new-onset period had split results: teplizumab, ChAglyCD3, linomide, and atorvastatin performed better compared to placebo in groups with better baseline beta cell function measures 35,49,55,56,83. In contrast, canakinumab, imatinib mesylate, and the anti-IL-21/liraglutide combination showed stronger treatment effects in individuals with lower baseline beta cell function measures 42,68,84. Taken in aggregate these results highlight evidence that baseline beta cell function may impact treatment response, but the direction of impact likely varies by treatment used and stage of disease.
Interestingly, in contrast to primary trial papers, precision papers most commonly tested relationships of an immune cell phenotype with treatment response (57%). Because only two papers identified included a favorable response to time to type 1 diabetes diagnosis, treatment response was assessed using a range of alternative outcomes (Fig. 4D). For all types of papers, a measure of C-peptide was most commonly used as an alternative outcome to gauge treatment response (range of 44-68%).

Risk of Bias/Quality Assessments

A finding impacting studies in all categories was a lack of racial and ethnic diversity in participant populations. Data on participant race was available in less than a third (23/75) of total papers; for reported papers, participants self-reporting as white race comprised a median of 92% of the total study population (interquartile range of 88-96%). Ethnicity was reported in 20 papers; within these manuscripts, participants self-reporting as identifying with a Hispanic ethnicity comprised a median of 5% of study participants (interquartile range of 3-9%).

When assessing additional risks of bias, we found that many papers did not include details sufficient to assess these risks (Fig. 5). Although over half of primary trial papers were considered to utilize high quality methods for sequence generation and allocation concealment, 32-37% did not describe methods adequately for assessment. Follow-up and precision papers infrequently described these methods, commonly citing a primary trial paper instead (75-100%). Blinding was described more frequently, with at least double blinding in 63-74% of follow-up and primary trial papers, although 23-25% had
single or no blinding. In contrast, blinding of outcome assessments was either not described or did not occur in 79% of primary trial papers. Most precision papers referenced primary papers and so blinding was challenging to assess. Completeness of outcome data reporting was assessed by considering reasons and numbers for attrition or exclusion in studies. Reporting of outcome was overall high quality for trials and follow-up studies (75-79%). This was less frequently the case for precision papers, only half of which reported on reasons for incomplete outcome data. While the large majority (87%) of trial papers described a prespecified primary endpoint, only 75% of follow-up papers and 21% of precision papers solely included analyses that were noted to be prespecified. Additional sources of bias were identified in 33/75 total papers (44%), these biases were also acknowledged by study authors. These were most frequently acknowledged funding or support by a pharmaceutical company. However, another source of bias that was not addressed as a limitation by the authors was identified in 3 papers (all primary trial papers). No concerns for other unacknowledged sources of bias were identified in follow-up studies and precision studies.

Conclusions

We systematically reviewed 25 years of large (n>=50 participants) randomized controlled trials focused on disease modifying agents in T1D and analyses focused on identifying features of treatment response to these agents. Our search identified 17 agents, mostly immunotherapies, that have shown benefit compared to placebo (though only two prior to clinical diabetes onset). We found most precision subgroup analyses were included as components of manuscripts reporting primary outcomes of trials. The
analyses most commonly focused on age or a measure of beta cell function as potential features that may identify individuals with better responses to specific disease-modifying therapies. We also identified stand-alone papers focused on understanding treatment response. Immune phenotypes were most commonly assessed as features to define heterogeneity of treatment response in these papers.

Time to T1D was the most consistent primary outcome of T1D prevention studies, but inclusion criteria for these studies varied widely across trials and included genetic risk, presence of islet autoantibodies, and changes in glycemia and/or beta cell function. Most intervention studies were in new-onset T1D and the vast majority of these new-onset studies analyzed impacts on C-peptide AUC during a mixed meal test as a primary outcome, consistent with the consensus recommendations by Palmer and colleagues. Most new-onset studies identified had similar inclusion criteria, with ~10% of studies specifying a primary analysis of a more precise subgroup of individuals for study based on specific autoantibody positivity. The majority of trials at onset of disease likely reflects the longstanding precedent of defining T1D by established clinical criteria (established due to the link with future risk of complications). A key consideration is the appealing risk-benefit balance of giving immunotherapy to individuals with a clinical T1D diagnosis, compared to persons at-risk who may never go on to develop T1D. Recent progress in understanding the natural history of T1D, particularly the high risk associated with progression from multiple autoantibodies to clinical T1D, has led to a definition of stage 1 and stage 2 defined by the presence of autoantibodies and dysglycemia respectively. The combination of defining pre-clinical stages 1 and 2
and the recent positive trial of teplizumab in stage 2 may change the balance of prevention versus new onset trials in the future.

A challenge within the field has been a clear and consistent delineation of the definition of intervention "responders" within larger trial populations. Strategies have included consideration of time to diabetes, insulin use, stratification based on changes in C-peptide, and identification of individuals exhibiting less loss of C-peptide based on placebo controls \(^{16,24,56,62}\). Our review suggests that C-peptide is by far the most frequent outcome measure used to identify differential treatment responses, but approaches to stratify based on C-peptide were highly variable. Consistent approaches, such as a quantifiable metric based on expected values \(^{95}\) will allow better comparison of features associated with treatment response across trials.

Age and measures of beta cell function were most frequently identified as factors associated with differential treatment response in primary trial and primary trial follow-up papers. For example, younger age was linked to an improved treatment response in several new-onset trials using CD3-based agents \(^{49,53,56,82}\). The association of age with treatment response is in keeping with the strong associations of age to features of T1D in many observational and natural history studies, before and after clinical diagnosis \(^{10,96-98}\). Differences in pancreas histology have been identified in donors with younger age of diagnosis \(^{99,100}\). However, it is unclear whether differences in treatment response linked to age are associated with differences in underlying disease pathophysiology vs. differences in severity or progression of disease at the time of treatment. The
observation that age differentially impacts outcomes in different trials, in addition to stratification of both immune phenotypes and beta cell function by age, supports the idea that the underlying biological reasons for age associations could be linked to mechanism and are important to consider in future trial designs and potentially, in future precision therapy.

Importantly, 38% of studies testing impacts of baseline beta cell function showed a significant link to treatment response, consistent with the substantial body of literature identifying an ongoing dialogue between autoimmunity and the beta cell in T1D. Interestingly, findings somewhat differed depending on stage of intervention. Here, two unique prevention studies testing oral insulin and teplizumab showed that worse beta cell function was associated with improved treatment outcomes compared to placebo. In contrast, CD3-based therapy trials after disease onset showed an association between higher measures of beta cell function and improved outcomes. These differences highlight the importance of considering disease stage in design and interpretation of intervention efforts. Especially at earlier stages in the disease process, abnormalities in beta cell function could allow insight into a therapeutic window during active disease or immune attack, and optimal timing of therapy. In contrast, in more advanced disease after diagnosis, associations with differences in beta cell function could reflect differences in the degree of disease progression, and so amenability to prolonged preservation of a larger residual beta cell mass. Differences in the relationships between beta cell function measures and outcomes for different agents in the new onset period also highlight agent mechanism of action as a critical
consideration for designs incorporating beta cell function into stratification of trial populations and precision approaches to disease-modifying therapy.

Specific autoantibodies and immune cell phenotypes were also linked to treatment response for multiple agents. An important consideration in these types of assays is reproducibility. Harmonization to international criteria would facilitate cross-study comparisons and improve reproducibility, a critical challenge with functional immune markers. The T1D field has been strengthened by an international standardization program for autoantibody measurement that underpinned the development of type 1 diabetes staging criteria. An important consideration is that if novel mechanistic markers (immune, metabolic, or other) can be used to predict treatment response, then similar scrutiny and standardization of these markers will be needed. Pragmatic approaches to biomarker development need to include considerations of reproducibility to be successfully implemented.

Most studies reviewed did not report data on race or ethnicity; for those that did report these data, populations studied largely identified as non-Hispanic white. Barriers in screening of traditionally underrepresented populations is a recognized issue amongst T1D natural history and intervention studies. This is especially important to address moving forward given the rising incidence of T1D in these populations.

Our analysis identified important methodologic considerations with many precision analyses. Most trial manuscripts (primary or follow-up) included precision analyses that
were not prespecified. Corrections for multiple comparisons were rare. Additionally, subgroup sizes were infrequently reported, but when available, these group sizes were highly variable and as small as n=2 participants. Papers also tended to show positive results, raising concern for publication bias.

While these issues are a known limitation of hypothesis-generating exploratory analyses, follow-up studies focusing on testing these positive relationships a priori will be critical to the application of clinically meaningful precision medicine. An example of the necessity of hypothesis testing was the TrialNet oral insulin prevention study, which was prospectively designed to test a responder subgroup identified in the Diabetes Preventional Trial Type 1 (DPT-1) trial with high insulin autoantibody titers, and ultimately found no significant impact of treatment within this group \(^{114}\). Another example of a trial moving forward with prospective testing based on subgroup analyses is the DIAGNODE 3 study, which will prospectively test intralymphatic GAD-alum injections in the HLA DR3-DQ2 population (NCT05018585). This approach is based on a meta-analysis of subcutaneous GAD-alum trials \(^{115}\) and a small study of intralymphatic injections showing a preferential benefit vs. placebo in this population \(^{66}\). These studies were not included in the current review due to participant time from diagnosis and sample size. Prospective testing of potential responder subgroups is needed to validate findings before they can be integrated into precision approaches. Trials designed to limit participant heterogeneity based on features associated with treatment response may ultimately allow for clearer determinations of effect, and a greater number of positive trials.
This study had limitations. For feasibility, we restricted our review of primary trials to those enrolling a minimum of 50 total participants. Because of this, some trials were not reviewed, including positive trials testing alefacept \textsuperscript{116,117} and verapamil in the new onset period \textsuperscript{118}. A large pediatric follow-up trial testing verapamil (positive outcome) and tight metabolic control with hybrid closed loop (negative outcome) was published after conclusion of our systematic review \textsuperscript{119,120}.

In summary, our review identified significant progress towards defining effective disease-modifying therapies for T1D. Overall this work highlights the impact of consensus agreement on trial outcomes to allow between trial outcomes comparisons and standardization of precision measures to study subgroups of patients or at-risk individuals. Although many associations of interest have been identified, the impact and clinical utility of these observations is weakened by post-hoc study design. Pre-specified adequately powered subgroup analyses focused on age, beta cell function, HLA genotypes, and immune measures will allow stronger conclusions from future studies and should be considered when planning trials. Finally, reports of future trials would benefit from including adequate details to assess potential risks of bias.

**Acknowledgments:** We thank Krister Aronsson and Maria Bjorklund from Lund University for assistance with database searches and Russell de Souza from McMaster University for advice on critical appraisal.

**Funding sources:** JF: DiabDocs K12 program 1K12DK133995-01 (DiMeglio, Maahs PIs), The Leona M. & Harry B. Helmsley CharitableTrust Grant #2307-06126 (Felton PI)
KG: The Leona M. and Harry B. Helmsley Charitable Trust and Sanford Health. RAO: RAO had a UK MRC confidence in concept award to develop a type 1 diabetes GRS biochip with Randox R&D and has ongoing research funding from Randox; and has research funding from a Diabetes UK Harry Keen Fellowship (16/0005529), National Institute of Diabetes and Digestive and Kidney Diseases grants (NIH R01 DK121843–01 and U01DK127382–01), JDRF (3-SRA-2019–827-S-B, 2-SRA-2022–1261-S-B, 2-SRA-2002–1259-S-B, 3-SRA-2022–1241-S-B, and 2-SRA-2022–1258-M-B), and The Larry M and Leona B Helmsley Charitable Trust; and is supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Institutes for Health Research or the Department of Health and Social Care. LAD: NIH for TrialNet U01DK106993/6163-1082-00-BO, DiabDocs K12 program 1K12DK133995-01, CTSI UL1TR001108-01, CEM: R01DK093954, R01DK127236, U01DK127786, R01DK127308, and UC4DK104166, U54DK118638, P30 P30 DK097512), a US Department of Veterans Affairs Merit Award (I01BX001733), grants from the JDRF (3-IND-2022-1235-I-X) and Helmsley Charitable Trust (2207-05392), and gifts from the Sigma Beta Sorority, the Ball Brothers Foundation, and the George and Frances Ball Foundation. HI: K23DK129799; RJ: NIH R03-DK127472 and The Leona M. and Harry B. Helmsley Charitable Trust (2103-05094); SAL: NIH NIAID R01 AI141952 (PI), NIH NCI R01 CA231226 (Other support), NIH NIAID 1 R01HL149676 (Other support), NIH NIDDK 1UC4DK117483 (subaward), JDRF 3-SRA-2019-851-M-B; SOG: NIH R01 DK121843–01; SR: R01 DK122586, THE LEONA M AND HARRY B HELMSLEY CHARITABLE TRUST 2204-05134; JW: JDRF 2-SRA-2022-1282-M-X, 3-SRA-2022-
1095-M-B, 4-SRA-2022-1246-M-N, 3-SRA-2023-1374-M-N.; MR: NIH NIDDK R01DK124395 and R01DK121843; R01DK121929A1, R01DK133881, U01DK127786, U01 DK127382 (EKS). Effort from this grant (to EKS, HI, JF) is also supported by Grant 2021258 from the Doris Duke Charitable Foundation through the COVID-19 Fund to Retain Clinical Scientists collaborative grant program and was made possible through the support of Grant 62288 from the John Templeton Foundation.

Author contributions: JLF, KJG, RAO, MJR and EKS designed the project, performed systematic review, interpreted results, and wrote and edited the manuscript. CS, SAL, SOG, SSR, GSFM, CEM, LAD, HMI, AKS, DD, RKJ, MU, SG, and JMW contributed to design of the project, performed systematic review, and edited the manuscript.

Competing Interests: EKS has received compensation for educational lectures from Medscape, ADA, and MJH Life Sciences and as a consultant for DRI Healthcare. CEM reported serving on advisory boards for Provention Bio, Isla Technologies, MaiCell Technologies, Avotres, DiogenyX, and Neurodon; receiving in-kind research support from Bristol Myers Squibb and Nimbus Pharmaceuticals; and receiving investigator-initiated grants from Lilly Pharmaceuticals and Astellas Pharmaceuticals. LAD reports research support to institution from Dompe, Lilly, Mannkind, Provention, Zealand and consulting relationships with Abata and Vertex. RAO had a UK MRC Confidence in concept grant to develop a T1D GRS biochip with Randox Ltd, and has ongoing research funding from Randox R & D. No other authors report any relevant conflicts of interest.
Data Availability statement: all studies reviewed were identified via publically available databases (PubMed and Embase). Article review data supporting the findings of this study are available upon reasonable request from the corresponding author.
<table>
<thead>
<tr>
<th>Trial acronym</th>
<th>Population</th>
<th>Intervention</th>
<th>Multi-center</th>
<th>Blinding</th>
<th>Primary Outcome</th>
<th>Follow-up duration</th>
<th>Positive?</th>
<th>Hazard ratio (95%CI) vs control</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Prevention Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hummel 2011 (BABYDIET)</td>
<td>150 infants with a first-degree family history of T1D and high-risk HLA genotypes</td>
<td>Late (12 mo.) vs. early (6 mo.) gluten exposure</td>
<td>No</td>
<td>None</td>
<td>Aabs</td>
<td>3 yrs (range 3.0-10.0)</td>
<td>No</td>
<td>1.3 (0.6-3.0)</td>
</tr>
<tr>
<td>Vaarala 2012 (FINDIA)</td>
<td>1113 infants with high-risk HLA genotypes</td>
<td>Whey-based hydrolyzed vs. cow's milk formula</td>
<td>Yes</td>
<td>Double</td>
<td>Aabs</td>
<td>n/a</td>
<td>Yes</td>
<td>0.82 (0.38-1.7)</td>
</tr>
<tr>
<td>Knip 2018 (TRIGR)</td>
<td>2159 infants with a first-degree family history of T1D and high-risk HLA genotypes</td>
<td>Extensively hydrolyzed casein formula vs. conventional formula</td>
<td>Yes</td>
<td>Double</td>
<td>Time to diabetes</td>
<td>11.5 yrs (Q1-Q3, 10.2-12.8)</td>
<td>No</td>
<td>1.1 (0.8 to 1.5)</td>
</tr>
<tr>
<td><strong>Secondary Prevention Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Näntö-Salonen 2008</td>
<td>264 infants with high-risk HLA genotype and their siblings with high-risk HLA and multiple Aab+</td>
<td>Intranasal daily recombinant human short-acting insulin vs. placebo</td>
<td>Yes</td>
<td>Double</td>
<td>Insulin: 1.7 yrs (IQR 0.7-3.0) Placebo: 2.0 yrs (IQR 0.8-3.2)</td>
<td>No</td>
<td>1.2 (0.68-2.0)</td>
<td>Infants: 1.2 (0.67-1.4)</td>
</tr>
<tr>
<td>Lampeter 1998 (DENIS)</td>
<td>55 Islet-cell Aab+ siblings of individuals with T1D</td>
<td>1.2 g/m2/day Endur-Aamide (nicotinamide) vs. placebo</td>
<td>Yes</td>
<td>Double</td>
<td>Time to diabetes</td>
<td>2.1 yrs, maximum 3.8</td>
<td>No</td>
<td>0.79 (0.25-3.4)</td>
</tr>
<tr>
<td>Gale 2004 (ENDIT)</td>
<td>552 Islet-cell Aab+ relatives with nondiabetic OGTT</td>
<td>1.2 g/m2 po modified release nicotinamide x 5 years vs. placebo</td>
<td>Yes</td>
<td>Double</td>
<td>Time to diabetes</td>
<td>5 yrs (intended for all, but only reached by 88%)</td>
<td>No</td>
<td>1.1 (0.78, 1.5)</td>
</tr>
<tr>
<td>Skyler 2002 (DPT-1)</td>
<td>339 Islet-cell Aab+ first degree relatives with absence of low-risk HLA</td>
<td>0.25U/kg ultralente + annual 4-day continuous insulin</td>
<td>Yes</td>
<td>None</td>
<td>Time to diabetes</td>
<td>1345 days, IQR 784-1737</td>
<td>No</td>
<td>0.96 (0.69-1.3)</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Intervention</td>
<td>Outcome Measures</td>
<td>Time to Diabetes</td>
<td>Other Notes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>------------------</td>
<td>------------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skyler 2005</td>
<td>372 Islet-cell and insulin Aab + relatives with absence of low-risk HLA, higher first phase insulin response and normal OGTT</td>
<td>Oral insulin (7.5 mg/day) vs. placebo</td>
<td>Yes</td>
<td>Double</td>
<td>Time to diabetes: 4.3 yrs (IQR: 928-1988 days), 9.1 years, n/a</td>
<td>0.76 (0.51,1.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehik 2011</td>
<td>638 from parenteral and oral insulin trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butty 2008</td>
<td>303/372</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Krischer 2017</td>
<td>560 Multiple Aab+ relatives with insulin Aab+ and high or low first phase insulin response</td>
<td>7.5 mg daily po recombinant human insulin vs. placebo</td>
<td>Yes</td>
<td>Double</td>
<td>Time to diabetes: 2.7 yrs (IQR 1.5-4.7 yrs), n/a</td>
<td>0.83 (0.1-0.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sosenko 2020</td>
<td>208 with high DPTRS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Precision)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elding Larsson 2018</td>
<td>50 Multiple Aab+ children with GAD Ab+</td>
<td>20 ug sc injections of GAD-Alum monthly x 2 vs. placebo</td>
<td>No</td>
<td>Double</td>
<td>Other: safety</td>
<td>4.92 years (range: 0.47-5.0), n/a</td>
<td>0.77 (0.30, 1.9)</td>
<td></td>
</tr>
<tr>
<td>(DiAPREV-IT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herold 2019</td>
<td>76 Multiple Aab+ relatives with dysglycemia</td>
<td>14-day course of IV Teplizumab vs. placebo</td>
<td>Yes</td>
<td>Double</td>
<td>Time to diabetes: 745 days (range 74-2683), 923 days</td>
<td>0.41(0.22-0.78)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(TN10)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sims 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Follow-up or precision studies describing a randomized trial that is already included in the table are listed as bulleted subheadings.

T1D - Type 1 Diabetes, HLA - Human Leukocyte Antigen, Aab – Autoantibody, FINDIA – Finnish Dietary Intervention Trial for the Prevention of Type 1 Diabetes, n/a – not applicable, TRIGR – Trial to Reduce IDDM in the Genetically at Risk, Aab+ - Autoantibody Positive, DENIS – The Dutch Nicotinamide Intervention Study, ENDIT – European Nicotinamide Diabetes Intervention Trial, OGTT – Oral Glucose Tolerance Test, Po – per oral/orally, DPT-1 - Diabetes Prevention Trial Type 1 Diabetes, F/u – Follow-up, TN07 – TrialNet 07 trial, DPTRS - Diabetes Prevention Trial-Type 1 Risk Score, DiAPREV-IT – Diabetes Prevention – Immune Tolerance Trial, GAD Glutamic acid decarboxylase, Sc – subcutaneous, TN10 – TrialNet 10 trial, IV - intravenous
References


65 Ludvigsson, J. *et al.* Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type i diabetes: Lessons from the


77 Pozzilli, P. *et al.* Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. *J Clin Endocrinol Metab* **105** (2020). https://doi.org:10.1210/clinem/dgaa149


79 Pozzilli, P. *et al.* Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the
https://doi.org/10.1056/NEJMoa2006136

https://doi.org/10.2337/dc08-2029

https://doi.org/10.1016/s0140-6736(11)60931-8

https://doi.org/10.1371/journal.pone.0033108

https://doi.org/10.1016/s2213-8587(21)00019-x

https://doi.org/10.2337/dc09-0449

https://doi.org/10.1016/s0140-6736(11)60895-7

https://doi.org/10.1056/NEJMoa012350

https://doi.org/10.1056/NEJMoa1902226

https://doi.org/10.1111/pedi.12611

https://doi.org/10.2337/diabetes.53.1.250

https://doi.org/10.2337/dc23-S002


106 Marre, M. L. et al. Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4(+) T Cells in Patients With
Type 1 Diabetes. *Diabetes* 67, 1356-1368 (2018). [https://doi.org/10.2337/db17-1166](https://doi.org/10.2337/db17-1166)


113 Divers, J. M.-D., E; Lawrence, JM; Isom, S; Dabelea, D; Dolan, L; Imperatore, G; Marcovina, S; Pettitt, DJ; Pihoker, C; Hamman, RF; Saydah, S; Wagenknecht, LE. Trends in Incidence of Type 1 and Type 2 Diabetes Among Youths — Selected Counties and Indian Reservations, United States, 2002–2015. . *MMWR Morb Mortal Wkly Rep* 69, 161-165 (2020). [https://doi.org/http://dx.doi.org/10.15585/mmwr.mm6906a3](https://doi.org/http://dx.doi.org/10.15585/mmwr.mm6906a3)


115 Hannelius, U., Beam, C. A. & Ludvigsson, J. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes. *Diabetologia* 63, 2177-2181 (2020). [https://doi.org/10.1007/s00125-020-05227-z](https://doi.org/10.1007/s00125-020-05227-z)


**Figure 1. Consort diagram.** Flowchart displaying studies screened, and excluded as part of abstract screening, then via full text review/eligibility assessment. 75 total papers were included in extraction. AUC - area under the curve; T1D - Type 1 diabetes.
Figure 2. Relative effect of prevention therapies in individuals at-risk for T1D. Forest plot showing hazard ratio for primary prevention studies in genetically at-risk individuals and secondary prevention studies in individuals with elevated islet autoantibody titers. Primary prevention studies are divided by outcome—either time to islet autoantibody positivity or time to diabetes. All secondary prevention studies used time to diabetes as a primary outcome. DPT1 – Diabetes Prevention Trial Type 1; GAD– Glutamic acid decarboxylase
Figure 3. Precision analyses focused on treatment response were mostly part of primary trial papers, tended to be post-hoc, and were biased toward positive findings. A. Dot plot showing breakdown of the 57 papers that included precision analyses. These were 67% primary trial papers, 24% manuscripts that focused on precision analyses related to treatment response, and 9% longitudinal follow-up papers presenting updates on primary trial results. B. Stacked bar graphs showing relative frequencies of papers with precision analyses that were defined as prespecified in the manuscript text. C. Stacked bar graph displaying relative frequencies of papers reporting positive findings related to associations with treatment effects. D. For papers that listed sample sizes of subgroups tested for differential treatment effects (only 53% of all papers with precision analyses), the smallest samples size reported is displayed, with mean and SEM indicated. F/u- follow-up.
Figure 4. Precision analyses tested many features, most commonly age and beta cell function, infrequently corrected for multiple comparisons, and typically tested for differential impacts on a C-peptide based measure. A. Total number of features tested for association with each treatment response, with mean and SEM indicated. B. Stacked bar graph showing relative frequencies of papers that did or did not correct for multiple comparisons. C. Relative frequencies of individual features tested for associations with treatment response. D. Relative frequencies of outcomes utilized to assess for the presence of any features associated with differential treatment response. F/u – follow-up, fx – function, Hba1c – Hemoglobin A1c, Aab – Autoantibody, HLA – Human Leukocyte Antigen, BMI – Body Mass Index, T1D – Type 1 Diabetes, AGT – Abnormal Glucose Tolerance, CRP – C-reactive Protein, DPTRS – Diabetes Prevention Trial-Type 1 Risk Score, DKA – Diabetes Ketoacidosis, Dx - diagnosis
Figure 5. Risk of bias assessments for each paper category. Bias was assessed using Covidence’s Cochrane risk of bias tool. For sequence generation, allocation concealment, and blinding categories, raters had the option of selecting high quality (green), low quality (orange), not reported (red), or that a decision could not be made because of primary trial was referenced in methods (yellow). For incomplete outcome data, raters only had the option to choose high quality/data provided (green) or low quality/data not provided (red). For selective reporting, raters had the option to select high quality/primary endpoint predefined (green), low quality/primary endpoint not defined (orange) or low quality/not reported (red). For other sources of bias, raters had the option to select high quality/note (green), low quality/bias present but identified and considered (orange), or low quality/obvious bias present and not addressed (red).